| Trial ID: | L1448 |
| Source ID: | NCT02335099
|
| Associated Drug: |
Ticagrelor
|
| Title: |
Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02335099/results
|
| Conditions: |
End Stage Renal Disease|Vascular Access Patency
|
| Interventions: |
DRUG: ticagrelor|DRUG: Placebo
|
| Outcome Measures: |
Primary: Feasibility and Safety of Ticagrelor in Hemodialysis Patients, Number of Participants with prolonged bleeding (\>30 minutes) after removal of needles, 6 months | Secondary: Treatment Efficacy of Ticagrelor to Preserve Patency of Hemodialysis Vascular Access, Percentage of participants with stenosis free survival, 1 year
|
| Sponsor/Collaborators: |
Sponsor: University of Virginia | Collaborators: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
54
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2014-12
|
| Completion Date: |
2019-06
|
| Results First Posted: |
2022-06-08
|
| Last Update Posted: |
2022-06-08
|
| Locations: |
University of Virginia - Hospital West Kidney Center Dialysis, Charlottesville, Virginia, 22908, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02335099
|
